References
- Blumenauer B, Judd M, Wells G et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev.3, CD003785 (2002).
- Blumenauer B, Judd M, Cranney A et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev.4, CD004525 (2003).
- Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst. Rev.3, CD005113 (2005).
- Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs23(2), 111–124 (2009).
- Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med.344(12), 907–916 (2001).
- Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J. Rheumatol.37(2), 234–245 (2010).
- Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med.144(12), 865–876 (2006).
- Kremer JM, Genant HK, Moreland LW et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum.58(4), 953–963 (2008).
- Genant HK, Peterfy CG, Westhovens R et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann. Rheum. Dis.67(8), 1084–1089 (2008).
- Kremer JM, Russell AS, Emery P et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann. Rheum. Dis.70(10), 1826–1830 (2011).
- Galloway JB, Hyrich KL, Mercer LK et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology50(1), 124–131 (2011).
- Strangfeld A, Eveslage M, Schneider M et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann. Rheumatic Dis.70(11), 1914–1920 (2011).
- Singh JA, Christensen R, Wells GA et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med. J.128(5), 309–310 (2010).
- Schiff M, Keiserman M, Codding C et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST study. Ann. Rheumatic Dis.70(11), 2003–2007 (2011).
- Haggerty HG, Abbott MA, Reilly TP et al. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J. Rheumatol.34(12), 2365–2373 (2007).
- National Institute for Health and Clinical Excellence. Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti- rheumatic drugs London: National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 195 (2011).
- Genovese MC, Covarrubias A, Leon G et al. Subcutaneous abatacept versus intravenous abatacept: a Phase 3b noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum.63(10), 2854–2864 (2011).